Novo and Lilly contender Zealand Pharma heralds its obesity drug alternative: It’s our ‘crown jewel’

Home » Blog » Novo and Lilly contender Zealand Pharma heralds its obesity drug alternative: It’s our ‘crown jewel’

October 12, 2024October 12, 2024

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly.

Previous PostHow Russia’s war economy and defense spending could actually make it weakerNext PostNobel Peace Prize 2024 awarded to Japanese atomic bomb survivor organization Nihon Hidankyo

Latest Articles

How Elon Musk’s plan to slash government agencies and regulation may benefit his empire
Why X’s new terms of service are driving some users to leave Elon Musk’s platform
The Pentagon’s battle inside the U.S. for control of a new Cyber Force
Top 10 S&P 500 stock winners since Election Day
Donald Trump chooses hedge fund executive Scott Bessent for Treasury secretary
Amazon to invest another $4 billion in Anthropic, OpenAI’s biggest rival
Indonesia wants Apple to sweeten its $100 million proposal as tech giant lobbies for iPhone 16 sales
One of the world’s richest families plans to create Paris’s next big soccer success
U.S. embassy in London reopens after suspicious ‘hoax’ item found
Apple and Google could face a competition probe over their huge mobile ecosystems in the UK

Advertising

GTR provides global news on topics ranging from world markets, investing opportunities, industry analysis and so much more.

News

Finance
Investments
Technology

Countries

Worldwide
Africa
Asia
Australia
Canada
Europe
United States

Official

Magazines
Videos
About Us
Contact Us
Privacy
Terms & Conditions